Parallel Advisors’s Immunocore IMCR Stock Holding History

Parallel Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.6K	Buy	917 +38	+4%	+$1.23K	﹤0.01%	2321
2025 Q4	$30.5K	Sell	879 -36	-4%	-$1.27K	﹤0.01%	2099
2025 Q3	$33.2K	Sell	915 -91	-9%	-$3.09K	﹤0.01%	2004
2025 Q2	$31.6K	Hold	1,006	–	–	﹤0.01%	1971
2025 Q1	$29.8K	Hold	1,006	–	–	﹤0.01%	1929
2024 Q4	$29.7K	Buy	1,006 +9	+0.9%	+$285	﹤0.01%	1946
2024 Q3	$31K	Hold	997	–	–	﹤0.01%	1849
2024 Q2	$33.8K	Hold	997	–	–	﹤0.01%	1727
2024 Q1	$64.8K	Buy	997 +47	+5%	+$3.23K	﹤0.01%	1377
2023 Q4	$64.9K	Hold	950	–	–	﹤0.01%	1309
2023 Q3	$49.3K	Buy	950 +185	+24%	+$10.9K	﹤0.01%	1402
2023 Q2	$45.9K	Buy	765 +758	+10,829%	+$43.3K	﹤0.01%	1435
2023 Q1	$346	Sell	7 -31	-82%	-$1.74K	﹤0.01%	3213
2022 Q4	$2.17K	Buy	38 +11	+41%	+$619	﹤0.01%	2651
2022 Q3	$1K	Buy	+27	New	+$1.29K	﹤0.01%	2933

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Parallel Advisors's IMCR Position: Q1 2026 in Review

Parallel Advisors increased its Immunocore (IMCR) stake by 4.3% in Q1 2026, buying an estimated $1.23K and bringing the position to 917 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2321.

Parallel Advisors first reported a position in IMCR in Q3 2022 and has held it in 15 quarters since. The position peaked at $64.9K in Q4 2023. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

Parallel Advisors held 917 shares of Immunocore worth $27.6K as of Q1 2026.
Parallel Advisors bought 38 Immunocore shares in Q1 2026, an estimated $1.23K.
Immunocore made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2321 holding.
Parallel Advisors first reported a position in Immunocore in Q3 2022 and has held it in 15 quarters since.
Parallel Advisors's Immunocore position peaked at $64.9K in Q4 2023.
142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.